Risk Factors for Relapsed DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Paolo Strati, MD, discussed a case of a 73-year-old woman with diffuse large B-cell lymphoma who progressed after second-line therapy.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Combining the glutaminase-1 inhibitor CB-839 and BCL-2 inhibitor venetoclax could be a new avenue for the treatment of diffuse large B-cell lymphoma.

In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

In the first article of a 2-part series, Herbert A. Eradat, MD, discusses the research down that led to the use of the immunotherapy polatuzumab vedotin in combination with chemotherapy for patients with diffuse large B-cell lymphoma.

A phase 2 clinical trial has demonstrated the potential of zanubrutinib combined with R-CHOP for the treatment of untreated diffuse large B-cell lymphoma with extranodal involvement.